Treatment Waning in Dutch Pharmaceutical Submissions: An Exploratory Study

Author(s)

Efe R1, Huis in 't Veld L2
1Zorginstituut Nederland, Diemen, NH, Netherlands, 2Zorginstituut Nederland, Diemen, Netherlands

OBJECTIVES: Economic assessments are of utmost importance in health policy to inform the allocation of scarce resources. However, these economic assessments often involve many uncertainties. One of these important uncertainties is the duration of treatment effect. Typically a treatment effect is shown within a study, yet it is unclear whether this treatment effect would hold after the duration of the study. To deal with this type uncertainty, the incorporation of treatment waning is recommended. Although this recommendation is in place, it remains unknown whether this has been frequently used in pharmaceutical submissions to Zorginstituut Nederland (ZIN). Therefore the aim of this study was to explore whether treatment waning was incorporated in past economic assessments.

METHODS: ZIN assessments of pharmaceutical submissions that included an economic assessment in the time period of 2020-2022 were obtained. Data was extracted regarding submission characteristics, disease area, type of pharmaceutical and type of model, amongst others. Most importantly, the method to incorporate treatment waning was extracted.

RESULTS: Preliminary results show that of the 36 included economic assessments, 15 (42%) included treatment waning. Six (17%) included treatment waning in the base-case analysis and 9 (25%) included treatment waning in a sensitivity analysis. The methods to incorporate treatment waning were: gradual decreasing OS after certain time point (n=7), decreasing treatment effect with a certain percentage (n=1), changing health states after certain years (n=3) and changing regression coefficients (n=1). In 3 cases ZIN recommended treatment waning but it was not included in the final submission.

CONCLUSIONS: The majority of Dutch submissions ignore treatment waning, and when it is included, various methods were used. Currently, no clear guidelines on how and when to incorporate treatment waning are available. Future research should explore more robust methodologies to incorporate treatment waning in economic assessments.

Conference/Value in Health Info

2024-11, ISPOR Europe 2024, Barcelona, Spain

Value in Health, Volume 27, Issue 12, S2 (December 2024)

Code

HTA204

Topic

Clinical Outcomes, Economic Evaluation, Health Technology Assessment

Topic Subcategory

Comparative Effectiveness or Efficacy, Cost-comparison, Effectiveness, Utility, Benefit Analysis, Decision & Deliberative Processes

Disease

Drugs, No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×